Rusty Page - Neuronetics Senior Quality
| STIM Stock | USD 4.94 0.12 2.37% |
Executive
Rusty Page is Senior Quality of Neuronetics
| Address | 3222 Phoenixville Pike, Malvern, PA, United States, 19355 |
| Phone | 610 640 4202 |
| Web | https://neurostar.com |
Neuronetics Management Efficiency
The company has return on total asset (ROA) of (0.1707) % which means that it has lost $0.1707 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4819) %, meaning that it created substantial loss on money invested by shareholders. Neuronetics' management efficiency ratios could be used to measure how well Neuronetics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of March 2025, Return On Tangible Assets is likely to drop to -0.26. In addition to that, Return On Capital Employed is likely to drop to -0.3. At this time, Neuronetics' Net Tangible Assets are very stable compared to the past year. As of the 19th of March 2025, Other Current Assets is likely to grow to about 8.8 M, while Non Current Assets Total are likely to drop about 13.4 M.Neuronetics currently holds 62.47 M in liabilities with Debt to Equity (D/E) ratio of 0.63, which is about average as compared to similar companies. Neuronetics has a current ratio of 3.94, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Neuronetics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Benjamin JD | Sera Prognostics | 46 | |
| Joseph Vitale | Sotera Health Co | N/A | |
| Claudia Levi | DarioHealth Corp | N/A | |
| MBA MS | Exagen Inc | 46 | |
| Austin Aerts | Sera Prognostics | 38 | |
| Mary Mooney | DarioHealth Corp | N/A | |
| Xiaozhi Hu | Burning Rock Biotech | N/A | |
| Kieran OKane | Biodesix | 48 | |
| Brian Harrigan | DarioHealth Corp | N/A | |
| Lara Dodo | DarioHealth Corp | N/A | |
| Mark DeBlock | Biodesix | N/A | |
| Limor Drezner | DarioHealth Corp | N/A | |
| Michael MD | Exagen Inc | 70 | |
| Hao Liu | Burning Rock Biotech | 51 | |
| Jeffrey Black | Exagen Inc | 56 | |
| John Wegener | Exagen Inc | 55 | |
| Tomer BenKiki | DarioHealth Corp | 54 | |
| Kat Parrella | DarioHealth Corp | N/A | |
| Jessica Olbricht | Biodesix | N/A | |
| Mona Dean | DarioHealth Corp | N/A | |
| Dror Bacher | DarioHealth Corp | 49 | |
Management Performance
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.17 |
Neuronetics Leadership Team
Elected by the shareholders, the Neuronetics' board of directors comprises two types of representatives: Neuronetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neuronetics. The board's role is to monitor Neuronetics' management team and ensure that shareholders' interests are well served. Neuronetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neuronetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rusty Page, Senior Quality | ||
| Lisa MetznerRosas, Senior Officer | ||
| Andrew Macan, Gen VP | ||
| Claire Sears, VP Marketing | ||
| Andrew JD, GC, VP | ||
| Rick Grubbs, Senior Accounts | ||
| Cory Anderson, Senior Clinical | ||
| Kara Thornton, VP Director | ||
| Stephen MS, CFO VP | ||
| Sara Grubbs, Senior Officer | ||
| Keith Sullivan, CEO President |
Neuronetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neuronetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.58) % | ||||
| Operating Margin | (0.49) % | ||||
| Current Valuation | 357.22 M | ||||
| Shares Outstanding | 64.88 M | ||||
| Shares Owned By Insiders | 9.43 % | ||||
| Shares Owned By Institutions | 57.83 % | ||||
| Number Of Shares Shorted | 1.6 M | ||||
| Price To Book | 10.40 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.37) | Revenue Per Share | Quarterly Revenue Growth 0.107 | Return On Assets | Return On Equity |
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.